Previous 10 | Next 10 |
– Lumasiran Demonstrated a 72 Percent Mean Reduction in Urinary Oxalate and Improvements in Nephrocalcinosis in ILLUMINATE-B Phase 3 Study in Children Under the Age of Six and as Young as Three Months – – Alnylam Also Presents New Results from ...
In 1962, the Nobel Prize was awarded to Francis Crick and James Watson for their discoveries related to deoxyribonucleic acid (DNA), the genetic code that provides instructions to cells. Messenger ribonucleic acid (mRNA), the intermediate step between DNA and proteins, can be bound and degr...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
The European Medicines Agency's advisory group CHMP adopts a positive opinion recommending approval for Alnylam Pharmaceuticals's (ALNY) lumasiran, RNAi therapeutic targeting the hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1 ((PHI)), a rare disord...
– Positive Opinion is Based on Results from ILLUMINATE-A and ILLUMINATE-B Phase 3 Studies – – European Commission Decision on Approval Expected in Q4 2020 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics compan...
Takeda and Arrowhead agree to a partnership on Arrowhead's ARO-AAT, with Takeda getting U.S. co-promotion rights and exclusive ex-US rights. Arrowhead is getting $300 million upfront, up to $740 million in future milestone payments, U.S. co-promotion rights, and 20% to 25% royalties o...
Arcutis receives a boost with positive seborrheic dermatitis study data. Integra LifeSciences to divest extremity orthopedics business. Alnylam announces positive data from Phase Lumasiran. For further details see: Arcutis Announces Positive Data, And Other News: The Goo...
Alnylam's announcement on ILLUMINATE-B was light on details, but management talked about "clinically significant" efficacy in young pediatric patients with PH1 and a clean safety profile. Management formalized its agreement with Blackstone concerning R&D funding for vitusiran and ...
Alnylam Pharmaceuticals (ALNY) announces positive results from an 18-subject, single-arm Phase 3 clinical trial, ILLUMINATE-B, evaluating RNAi therapeutic lumasiran in children under the age of six, including infants, with primary hyperoxaluria type 1 (PH1), a rare inherited kidney disorder c...
– First-Ever Study to Have Evaluated the Safety and Efficacy of an Investigational RNAi Therapeutic in Infants and Children Under the Age of Six – – Lumasiran Demonstrated Clinically Significant Reduction in Urinary Oxalate Levels Relative to Baseline ...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...